Tomorrow.Bio Funding News- Berlin-based Startup Tomorrow.Bio Raises €5M For U.S. Expansion

The company’s vision is to give people a second chance at life by preserving them until future medical advances can cure deadly diseases like lung cancer.

The €5 million seed round was co-led by early-stage VC Blast.Club and Truventuro, the family office of Nils Regge.

“We’re extremely happy to have found visionary investors to continue our long-term mission. Not only by expanding our coverage to the US but also by doubling down on R&D to further​ improve preservation quality and stay far ahead of all competition,” said Dr Emil Kendziorra, Founder and CEO of Tomorrow.Bio.

Tomorrow.Bio provides long-term cryopreservation services for people who choose to be stored at ultra-low temperatures after legal death, with the hope of being revived in the future when medical technology has advanced.

The company works closely with the European Biostasis Foundation (EBF) in Switzerland, where patients are stored in high-tech tanks filled with liquid nitrogen.

Read Also - Dutch VC firm Keen Venture Partners Raises EIF Backing For €40M Defence Tech Fund

So far, 20 people and 10 pets have been cryopreserved, and over 800 more have signed up. The total contract value has crossed €160 million.

Cryopreservation means cooling the body to -196°C to stop all biological activity after legal death. Tomorrow.Bio uses special cryo-ambulances to pick up the body and start the cooling process on the way to their facility in Switzerland.

Their “standby teams,” now based in Berlin and Zurich, act fast after legal death. They perform chest compressions, provide oxygen, and start cooling the body to slow down decomposition. More teams are being set up across Europe and the U.S.

They also replace body fluids with a cryoprotectant—an antifreeze-like solution that stops ice crystals from forming during freezing.

As Tomorrow.Bio expands into the U.S. and adds partner medical teams in at least three more locations, it aims to become the first company in the world with local teams ready to start the process right after legal death.

“Companies like Tomorrow Bio are on the absolute forefront of visionary longevity approaches. We’re very happy to support these types of moonshots, that might not just have a big impact on the extension of life span but are also huge business opportunities,” said Nils Regge, Founder of Truventuro and investor in longevity.

The company works closely with its sister organization, the European Biostasis Foundation, based in Rafz, Switzerland. This is where cryopreserved patients are stored in a high-tech facility.

Inside the facility, patients are kept in 3.2-meter-tall vacuum-insulated steel containers called dewars. These are filled with liquid nitrogen and stay cold without needing electricity.

“Tomorrow Bio’s cutting-edge technology is revolutionising the way we view life and death. The company has the necessary assets to overcome technological challenges and ensure sustainable growth. The ambitious yet realistic vision of the founders Emil and Fernando positions Tomorrow Bio as what could be the future of medicine,” said Anthony Bourbon, Founder and CEO of Blast.Club.

Tomorrow.Bio will use the funds to grow into the United States, starting in New York, California, and Florida. The company will also invest more in research and development to make their preservation methods even better.

About Tomorrow.Bio

Tomorrow.Bio was founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro. Kendziorra, a doctor and former cancer researcher, shifted careers after feeling that medical progress was too slow. Before starting Tomorrow.Bio, both founders had built and successfully exited tech startups.